Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R8ER
|
|||
| Former ID |
DAP001000
|
|||
| Drug Name |
Enoxacin
|
|||
| Synonyms |
Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Urinary tract infection [ICD-11: GC08; ICD-10: N39, N39.0; ICD-9: 599] | Approved | [1], [2] | |
| Therapeutic Class |
Antiinfective Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17FN4O3
|
|||
| Canonical SMILES |
CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
|
|||
| InChI |
1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
|
|||
| InChIKey |
IDYZIJYBMGIQMJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 74011-58-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9193, 494643, 598045, 855964, 7656850, 7847376, 7979166, 8149934, 8152051, 10321663, 11112842, 11335595, 11360834, 11364433, 11366995, 11369557, 11372679, 11373790, 11377719, 11414007, 11461806, 11466381, 11467501, 11485538, 11486102, 11489547, 11491385, 11491981, 11495353, 12012631, 14899277, 24894528, 26612426, 26680210, 26747059, 26747060, 29222370, 46507505, 47216718, 47365122, 47365123, 47440190, 47736413, 47885347, 48110393, 48110394, 48184940, 48334424, 48415943, 49698449
|
|||
| ChEBI ID |
CHEBI:157175
|
|||
| SuperDrug ATC ID |
J01MA04
|
|||
| SuperDrug CAS ID |
cas=074011588
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Bacillus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacillus was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Staphylococcus was not significantly changed by Enoxacin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroides was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Enoxacin (adjusted p-values: 1.25E-05). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Enoxacin (adjusted p-values: 5.82E-03). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Enoxacin (adjusted p-values: 6.13E-06). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Enoxacin (adjusted p-values: 7.50E-06). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Enoxacin (adjusted p-values: 1.71E-05). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Enoxacin (adjusted p-values: 1.69E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Enoxacin (adjusted p-values: 3.58E-05). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Enoxacin (adjusted p-values: 2.35E-05). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Enoxacin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Enoxacin (adjusted p-values: 3.17E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Enoxacin (adjusted p-values: 3.48E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was not significantly changed by Enoxacin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Enoxacin (adjusted p-values: 4.27E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eggerthella lenta was decreased by Enoxacin (adjusted p-values: 8.32E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacter was increased by Enoxacin. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was decreased by Enoxacin. | |||
|
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli ED1a was decreased by Enoxacin (adjusted p-values: 5.26E-06). | |||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Enoxacin (adjusted p-values: 4.93E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridioides difficile was decreased by Enoxacin (adjusted p-values: 3.42E-03). | |||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Enoxacin (adjusted p-values: 8.05E-07). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Enoxacin (adjusted p-values: 2.56E-05). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Enoxacin (adjusted p-values: 6.94E-03). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Enoxacin (adjusted p-values: 6.10E-06). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Enoxacin (adjusted p-values: 1.72E-03). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Enoxacin (adjusted p-values: 4.54E-03). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Enoxacin (adjusted p-values: 2.31E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Enoxacin (adjusted p-values: 1.39E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillus was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Streptococcus was not significantly changed by Enoxacin. | |||
|
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus salivarius was decreased by Enoxacin (adjusted p-values: 1.33E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Micrococcales | ||||
|
Studied Microbe: Micrococcaceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Micrococcaceae was not significantly changed by Enoxacin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Pseudomonadales | ||||
|
Studied Microbe: Pseudomonas
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Colonic content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Pseudomonas was increased by Enoxacin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Enoxacin (adjusted p-values: 5.04E-06). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Inhibitor | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Effect of enoxacin on colonic microflora of healthy volunteers. Eur J Clin Microbiol. 1987 Jun;6(3):298-300. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.